NASDAQ:TTHI

Transition Therapeutics (TTHI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.52
$1.52
50-Day Range
N/A
52-Week Range
$0.66
$2.75
Volume
N/A
Average Volume
70,238 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TTHI stock logo

About Transition Therapeutics Stock (NASDAQ:TTHI)

Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

TTHI Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Transition Therapeutics to Pay Eli Lilly $1M
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
US to end policy expelling migrants over Covid
Transition Stock Gaps Up On Today's Open (TTHI)
New Mask Rules In Malibu As State Mandate Returns
CareDx Completes Orderly Management Transition
See More Headlines
Receive TTHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Transition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:TTHI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

TTHI Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Transition Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Transition Therapeutics investors own include Telaria (TLRA), Himax Technologies (HIMX), Link Motion (LKM), Petróleo Brasileiro S.A. - Petrobras (PBR), Achillion Pharmaceuticals (ACHN), AcelRx Pharmaceuticals (ACRX), Acacia Research (ACTG), AK Steel (AKS), ALU (ALU) and Ambarella (AMBA).

This page (NASDAQ:TTHI) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners